Üks Life4me+ peamiseid eesmärke on uute HIVi- ja muude sugulisel teel levivate nakkuste juhtumite, nagu ka C-hepatiiti ja tuberkuloosi nakatumise ennetamine.

Nutirakendus aitab luua kontakti arstide ja HIV positiivsete inimeste vahel. Nutirakendus aitab mugavalt organiseerida ravimite võtmise aegu, seadistada ainult Teile arusaadavad ja personaalseid meeldetuletusi, võimaldab saada arstilt tagasisidet ning panna aega vastuvõtule või analüüsidele.

Tagasi
25 juuli 2017, 12:42
2356

WHO Announced the Prequalification of Sofosbuvir

WHO Announced the Prequalification of Sofosbuvir - pilt 1

The World Health Organization (WHO) has announced the prequalification of sofosbuvir, very significant drug for hepatitis C treatment and hardy available because of it’s high price. Drugs will be produced in 400 mg pills by Mylan Laboratories Ltd., India.By the prequalification process, the WHO hopes to ease the access to treatment by increasing the number of necessary generic medicines on the market.

“This is a break-through medicine with a 95% cure. The first WHO-prequalified generic of this product will give large procurers and countries the assurance of quality for an affordable product.” - said Dr Suzanne Hill, Director, Essential Medicines and Health Products at WHO.

WHO has also announced HIV-tests of the new type. New HIv tests will be oral ones and are giving the test results in 20 minutes. UN health agency hopes on the rise of HIV treatment diagnosing and care by making the tests easier in use.

“The prequalification of this product means that countries with poor laboratory infrastructure will be able to safely increase testing capacity, thereby facilitating treatment of people living with HIV,” said Dr Suzanne Hill, Director, Essential Medicines and Health Products, WHO.

The full WHO announcement is available on the official website of The World’s Health Organization.

Autor: Lilia Ten

Jaga suhtlusvõrkudes